Skip to main content
. Author manuscript; available in PMC: 2022 May 26.
Published in final edited form as: Diabetes Obes Metab. 2022 Jan 25;24(5):881–890. doi: 10.1111/dom.14646

Table 2:

Adverse Events

Adverse events related to study AZD4017 Placebo
Headache 8 4
Gastrointestinal: Diarrhea, softer stool, stomachache 9 6
Decreased appetite 1 0
Nausea 1 0
Difficulty swallowing due to large pill size 0 1
Tenderness at IV site 0 1
Lower extremity edema 0 1
Increased TSH 3 0

Abbreviations: IV, intravenous; TSH, thyroid-stimulating hormone.